| Literature DB >> 30228179 |
Dian Yang1,2,3, Sarah K Denny2,4, Peyton G Greenside5, Andrea C Chaikovsky1,2,3, Jennifer J Brady2, Youcef Ouadah1,6, Jeffrey M Granja2,4, Nadine S Jahchan2,3, Jing Shan Lim1,2,3, Shirley Kwok7, Christina S Kong7, Anna S Berghoff8,9,10, Anna Schmitt11, H Christian Reinhardt11,12,13, Kwon-Sik Park14, Matthias Preusser9,10, Anshul Kundaje2,15, William J Greenleaf2, Julien Sage16,2,3, Monte M Winslow16,2,7.
Abstract
The extent to which early events shape tumor evolution is largely uncharacterized, even though a better understanding of these early events may help identify key vulnerabilities in advanced tumors. Here, using genetically defined mouse models of small cell lung cancer (SCLC), we uncovered distinct metastatic programs attributable to the cell type of origin. In one model, tumors gain metastatic ability through amplification of the transcription factor NFIB and a widespread increase in chromatin accessibility, whereas in the other model, tumors become metastatic in the absence of NFIB-driven chromatin alterations. Gene-expression and chromatin accessibility analyses identify distinct mechanisms as well as markers predictive of metastatic progression in both groups. Underlying the difference between the two programs was the cell type of origin of the tumors, with NFIB-independent metastases arising from mature neuroendocrine cells. Our findings underscore the importance of the identity of cell type of origin in influencing tumor evolution and metastatic mechanisms.Significance: We show that SCLC can arise from different cell types of origin, which profoundly influences the eventual genetic and epigenetic changes that enable metastatic progression. Understanding intertumoral heterogeneity in SCLC, and across cancer types, may illuminate mechanisms of tumor progression and uncover how the cell type of origin affects tumor evolution. Cancer Discov; 8(10); 1316-31. ©2018 AACR. See related commentary by Pozo et al., p. 1216 This article is highlighted in the In This Issue feature, p. 1195. ©2018 American Association for Cancer Research.Entities:
Mesh:
Year: 2018 PMID: 30228179 PMCID: PMC6195211 DOI: 10.1158/2159-8290.CD-17-0987
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397